Greenphire, the leading provider of payment technology for the clinical trial industry, has launched a strategic partnership with ERT, a global leader in high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire’s ClinCard System with ERT’s best-in-class electronic patient reported outcomes (ePRO) technology.

“By incorporating our ClinCard technology with ERT’s remote collection of ePRO assessments we are able to enhance the value of our technologies to our joint clients,” said Kyle Cunningham, vice president of product management for Greenphire. “We know how vital accurate subject self-report data is to a clinical trial. By linking patient reporting to compensation, our clients can now enhance patient engagement between site visits and, consequently, improve compliance.”

This partnership will enable sponsors and CROs to offer real-time compensation to patients for compliance with study protocols by linking their ePRO activity to a ClinCard personal debit card. Now, in addition to using Greenphire’s system to compensate participants with stipends for site visits, clients can customize out-of-office reimbursement for patients’ time and effort based on the specific requirements of each protocol.

“This partnership is the next step forward in maximizing patient compliance,” commented Jim Corrigan, executive vice president and chief operating officer, ERT. “Patients are a trial’s most valuable asset and by combining ERT and Greenphire’s technology, sponsors and CROs will be able to have a simple, reliable communication link to patients as well as a seamless tool for reimbursing them for their time and expense.”

Sam Whitaker, co-founder and CEO of Greenphire added, “We are thrilled to be working with ERT on this game-changing partnership. ERT has built and deployed more than 100,000 ePRO devices through more than 100 international trials. Their track record speaks for itself and we look forward to providing this combined technology solution to help increase compliance, speed time-to-market, and boost return on investment for our clients who are developing life-saving treatments to meet global health needs.”